Alphabet’s AI-drug-discovery subsidiary, Isomorphic Labs has raised $600m in its first external funding round, backed by Thrive Capital and investment firm Tiger Global.
The company uses AI to discover and develop new drugs, and is working with Novartis and Eli Lilly.
OpenAI has raised 40bnatavaluationof300bn, with Microsoft remaining the sole bidder for the company; the financing will be used to “accelerate research and development”, according to OpenAI’s blog.
A new DeepMind-led study has demonstrated a neural speech prosthesis that enables people with paralysis to speak using their thoughts, rather than relying on sound or audio feedback.
Lepodisiran, a new injectable from Eli Lilly, has been shown to reduce lipoprotein(a) by up to 94% with six-month efficacy and no serious side effects; it’s ability to prevent heart attacks and strokes is still unproven, however.
